Colgate-Palmolive Q1: I Don't Think It Is Going To Outperform The Broader Index

The key takeaway is not the headline growth, but the widening quality gap between geographies. CL is proving it can still price and gain share in less defensive markets, while North America looks increasingly like a low-return drag where incremental freight/tariff noise is being absorbed with limited pricing power. That creates a subtle but important dynamic: the earnings base is becoming more dependent on regions with better elasticity and less promotional intensity, which should support multiple stability even if the domestic segment stays soft.

The SGPP expansion is more interesting as a medium-term margin option than as a near-term earnings driver. If management can actually convert supply chain redesign into $200m-$300m of pretax savings by 2028, that implies several hundred basis points of cumulative gross margin support relative to a flat-cost scenario, but the ramp will likely be back-end loaded and vulnerable to execution slippage. In the meantime, the market may underestimate how much offset CL can generate through productivity, which reduces the probability that North America weakness becomes a permanent earnings reset.

Second-order beneficiaries are the contract manufacturers, logistics operators, and input suppliers that can help CL re-engineer sourcing and inventory flows; the losers are domestic rivals with weaker scale and less room to absorb cost shocks. The main risk is that management uses productivity to defend volume rather than rebuild margin, which would delay EPS leverage for multiple quarters. A sharper reversal would come from relief on trade-related costs or freight normalization, which could make the current domestic profit compression look cyclical rather than structural.

Consensus likely treats this as a clean defensive staple story, but the more important question is whether the international mix improvement plus operating discipline can offset a stale North America base for long enough to matter. If the market is focused only on reported growth, it may be underpricing the option value of cost-out; if it is already assuming a full margin recovery, then the risk/reward is less attractive because the payback is spread over several years.